Ben Markman

4.6k citations
78 papers · 2.6k · 3 hit papers · h-index 25

Impact in

  • Oncology top 2%
    • Cancer Immunotherapy and Biomarkers
    • HER2/EGFR in Cancer Research
    • Colorectal Cancer Treatments and Studies
    • Lung Cancer Research Studies

Papers in

    • Cancer Immunotherapy and Biomarkers 18
    • Colorectal Cancer Treatments and Studies 13
    • Lung Cancer Research Studies 11
    • HER2/EGFR in Cancer Research 9
    • Cancer Treatment and Pharmacology 9
    • PI3K/AKT/mTOR signaling in cancer 7

Ben Markman

76 papers receiving 2.6k citations

Ben Markman's Hit Papers

A gut microbial signature for combination immune checkpoint blockade across cancer types 2024 · 79 citations
790+6+12Years since publication200400600

Peers

Ben Markman
Comparison fields: 5 of 95
  • Oncology 1.0k
  • Cancer Research 281
  • Molecular Biology 1.3k
  • Genetics 180
  • Pathology and Forensic Medicine 273
Replace Rebecca Kristeleit with:
Rebecca Kristeleit United Kingdom
Aya Kobayashi Japan
Jermaine Coward Australia
Agustin A. García United States
Akihiko Shimomura Japan
Andreas Pircher Austria
Phil F. Cheng Switzerland
Mohit Trikha United States
Argun Akçakanat United States
David Chen United States
Ben Markman relative to Rebecca Kristeleit United Kingdom Rebecca Kristeleit's profile →
Citations per field
00.5×1.5×1.9×
Rebecca Kristeleit · 1×
Citations per year

Countries citing papers authored by Ben Markman

Since Specialization
Citations

This map shows the geographic impact of Ben Markman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ben Markman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ben Markman more than expected).

Fields of papers citing papers by Ben Markman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ben Markman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ben Markman. The network helps show where Ben Markman may publish in the future.

Co-authors

The 25 scholars most cited alongside Ben Markman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ben Markman Line = papers co-authored together Ben Markman links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 78 papers — load more, or switch the sort, to bring in the rest.

#Work
1
NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
Hit paper breakdown →
2008653
2 2010279
3
Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers
Hit paper breakdown →
2020162
4 2009133
5 2020122
6 201096
7 201994
8 201488
9
A gut microbial signature for combination immune checkpoint blockade across cancer types
Hit paper breakdown →
202479
10 201169
11 201763
12 201945
13
Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors
202242
14 202338
15 201738
16 201837
17 201237
18 201735
19 201233
20 201832

About Ben Markman

Ben Markman is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research and Radiology, Nuclear Medicine and Imaging, having authored 78 papers that have together received 2.6k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (18 papers), Colorectal Cancer Treatments and Studies (13 papers), Lung Cancer Research Studies (11 papers), HER2/EGFR in Cancer Research (9 papers), Cancer Treatment and Pharmacology (9 papers), Lung Cancer Treatments and Mutations (9 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and PI3K/AKT/mTOR signaling in cancer (7 papers). The work is most often cited by research in Oncology (1.0k citations), Cancer Research (281 citations), Molecular Biology (1.3k citations), Genetics (180 citations) and Pathology and Forensic Medicine (273 citations). Ben Markman has collaborated with scholars based in Australia, United States and Spain. Frequent co-authors include Josep Tabernero, Rodrigo Dienstmann, José Baselga, Francesco Atzori, Maurizio Scaltriti, Josep Lluís Parra, Serena Di Cosimo, Elisabeth Llonch, Joaquı́n Arribas and María Luisa Botero. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Investigational New Drugs and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact